Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 9;41(3):1658–1668. doi: 10.3892/or.2019.6960

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zakelj et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Platinum and bleomycin accumulation in serum, tumors and cells after chemotherapy and electrochemotherapy with cisplatin or bleomycin. Platinum and bleomycin content in serum (A and B) and tumors (C and D) after i.v. injection of cisplatin (CDDP) or bleomycin (BLM) alone, or in combination with electric pulses (ECT) in radiosensitive (FaDu) and radioresistant (FaDu-RR) tumors. (E and F) The uptake of cisplatin in vitro. Data are represented as arithmetic mean (AM) and standard error of the mean (SEM) (AM ± SEM). (A-D) n=6; (E and F) n=3. *P<0.05 between FaDu and FaDu-RR tumors. **Data shown for cisplatin only; ***Exposure to 5 µM cisplatin for 5 min, or 2 h.